drugset
drugset / Trial / NCT03427853

A Study to Evaluate the Denosumab in Healthy Adults

NCT03427853 ↗

Phase 1 Unknown 32 enrolled Luye Pharma Group Ltd. Shandong Boan Biotechnology Co., Ltd · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a randomized, double-blind, parallel-group, placebo-controlled, single-dose escalation Phase I study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of denosumab injection administered subcutaneously to healthy adults in China

Timeline

Start
2018-01-10
Primary completion
2019-12-28
Completion
2019-12-28

Drugs

EvaluationDrugModalityDoseRoute
Subject LY06006 Monoclonal antibody 18 mg Subcutaneous
Subject LY06006 Monoclonal antibody 60 mg Subcutaneous
Subject LY06006 Monoclonal antibody 120 mg Subcutaneous

Indications

No indication recorded.